Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 127,008 |
|
|||||
| News | - | ||||||
| Day High | 19.48 | Low High |
|||||
| Day Low | 17.89 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| LENZ Therapeutics Inc | LENZ | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.09 | -0.48% | 18.54 | 23:00:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.89 | 17.89 | 19.48 | 18.54 | 18.63 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,047 | 127,008 | US$ 18.51 | US$ 2,351,537 | - | 14.42 - 24.59 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:31:14 | 71 | US$ 18.00 | USD |
LENZ Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 474.17M | 25.53M | - | 0 | -124.65M | -4.88 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
LENZ Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/10/2024 | 07:00 | GlobeNewswire Inc. | LENZ Therapeutics to Host Key Opinion Leader Event on June.. |
| 5/30/2024 | 07:00 | GlobeNewswire Inc. | LENZ Therapeutics to Present at the Jefferies Global.. |
| 5/21/2024 | 07:31 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 5/09/2024 | 15:18 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 5/08/2024 | 16:11 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/08/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/08/2024 | 15:01 | GlobeNewswire Inc. | LENZ Therapeutics Reports First Quarter 2024 Financial.. |
| 5/01/2024 | 15:01 | GlobeNewswire Inc. | LENZ Therapeutics to Report First Quarter Financial Results.. |
| 4/03/2024 | 06:00 | Business Wire | LENZ Therapeutics Announces Positive Topline Data from Phase.. |
| 4/02/2024 | 15:01 | Business Wire | LENZ Therapeutics to Host Investor Call to Discuss Topline.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LENZ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.04 | 19.98 | 14.9201 | 18.20 | 180,806 | 3.50 | 23.27% |
| 1 Month | 16.50 | 19.98 | 14.42 | 16.63 | 180,937 | 2.04 | 12.36% |
| 3 Months | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
| 6 Months | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
| 1 Year | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
| 3 Years | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
| 5 Years | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
LENZ Therapeutics Description
| Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. |
